NY-UNIFRAX/CLEARLAKE
21.4.2021 13:02:11 CEST | Business Wire | Press release
Unifrax , the leading manufacturer of high-performance specialty materials, today introduced FlexCat™ by Unifrax , a new high-surface area flexible media designed to provide enhanced catalyst effectiveness with increased yield using fewer raw materials. For use in fuel cells, specialty gas production, chemical processing, air purification and other applications, FlexCat offers catalyzers and industrial partners better performance, considerable cost savings, and improved safety for employees.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210421005357/en/
A game-changing solution for specialty catalyst markets
With many industries currently relying on alumina pellets to drive catalytic reactions, specialty chemical companies often grapple with stalled reactions because of clogged materials, large upfront investments and significant space requirements. They are also forced to contend with environmentally harmful emissions. To address these issues, Unifrax has designed a fibrous catalyst support solution that is 15 times lighter on average than the industry standard, while using significantly less precious metal catalysts and rare earth metals to drive an increase in yield while improving purity. This allows for increased output using existing equipment and enables a smaller reactor footprint for future designs. FlexCat can be incorporated into existing plant emission control systems to drive lower carbon footprints and allowing customers to meet tougher Environmental Protection Agency (EPA) standards.
“FlexCat is a truly revolutionary offering as a very lightweight, customized product form that is extremely durable in the harsh conditions typically encountered in many reactors,” said Chad Cannan, senior vice president of research and development, Unifrax. “FlexCat provides our industry partners with the potential to save millions of dollars across their operations in material costs, capital investments and improved quality from existing equipment. From cleaner emissions to meeting tougher EPA standards to increased purity, flow rates, and conversion speeds, the introduction of FlexCat is a true environmental, social, and governance (ESG) game changer for the industry.”
FlexCat is also poised to impact the hydrogen economy. As the demand for hydrogen increases, FlexCat supports the growth of hydrogen production through better selectivity and increased yield using significantly less catalyst material. FlexCat technology drives greater adoption by utilizing smaller and more efficient units that span from fuel cells to consumer devices.
Fiber-based technology that delivers
Leveraging the effective surface area of Unifrax’s unique fibrous material, FlexCat offers enhanced outputs by providing a more tortuous path for improved catalysis inside a reactor. FlexCat eliminates the need for any prewash or zeolite-coating process before applying catalyst metals. Testing to date has shown:
- Ability to use up to 80 percent less metal, including platinum group metals (PGMs), while obtaining the same conversion yield
- Extreme durability to nearly 1,850°F (~1,000°C) with more consistent product purity
- Enhanced conversion and selectivity of catalytic reactions, even after aging, allowing industrial plants better output with existing equipment
- Strong adhesion of PGMs and almost no loss of catalyst, even after thermal aging
FlexCat’s lightweight fiber mat structure allows for safer installation and removal, and limits hazardous waste, important benefits for Unifrax’s client’s workforce and the safety of the environment.
FlexCat and Unifrax’s deep technology portfolio
FlexCat is Unifrax’s first step into industrial catalysis, building on the company’s deep history of fiber-based technology and manufacturing. Unifrax has a track record of 75+ years developing and supplying engineered inorganic materials on a large scale to advanced industries worldwide, including electric vehicles, aerospace and chemical processing.
“Unifrax continues to pursue its mission to provide greener, cleaner, and safer solutions for our customers and partners. FlexCat is a revolutionary step forward for industrial catalysis that delivers on those three pillars,” commented John Dandolph, president and CEO, Unifrax. “Unifrax has worked closely with petrochemical and renewable fuels partners throughout our company’s history. As these industries look for new and innovative technologies to deliver cost-savings and efficiencies that current products can’t offer today, products like FlexCat, along with our new vehicle emissions technology Eco-lytic™ , deliver unique, game-changing solutions to catalysis industries overall. These products will have a transformational impact on safety, cost, and the environment in hundreds of industrial and chemical processes.”
Customizable for individual partners, processes and specific reactions, FlexCat can be manufactured at scale today. Unifrax will be available at Hydrogen 2021 Digital Conference & Exhibition to discuss in more with interested parties. For more information on the event visit this link .
Learn more about FlexCat at www.unifrax.com/landing-page/flexcat/ .
About Unifrax
Unifrax develops and manufactures high-performance specialty materials used in advanced applications, including high-temperature industrial insulation, electric vehicles, energy storage, filtration and fire protection, among many others. Unifrax products are designed with the ultimate goal of saving energy, reducing pollution and improving safety for people, buildings and equipment by delivering on our commitment to our customers of greener, cleaner, safer solutions for their application challenges. Unifrax has 37 manufacturing facilities operating in 12 countries and employs 2,700+ employees globally. More information is available at www.unifrax.com . For updates, follow us on Twitter , LinkedIn , and Facebook .
About Clearlake
Founded in 2006, Clearlake Capital Group, L.P. is an investment firm operating integrated businesses across private equity, credit and other related strategies. With a sector-focused approach, the firm seeks to partner with experienced management teams by providing patient, long-term capital to dynamic businesses that can benefit from Clearlake’s operational improvement approach, O.P.S.® The firm’s core target sectors are industrials, technology and consumer. Clearlake currently has approximately $35 billion of assets under management and its senior investment principals have led or co-led over 300 investments. The firm has offices in Santa Monica and Dallas. More information is available at www.clearlake.com and on Twitter @ClearlakeCap .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210421005357/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 16:00:00 CEST | Press release
As pharma manufacturers prioritize US supply chain resilience, highlights include high-speed isolator filling lines for prefilled syringes, cartridges and vials, and drug-device combination assembly and packaging. PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpi
Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 15:53:00 CEST | Press release
Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor
Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 15:00:00 CEST | Press release
Phase 1 dose-escalation trial represents the first clinical trial of a product developed using the AraLinQ™ ADC technology and marks Taiho’s expansion into the clinical development of ADCs for oncology Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug co
Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 15:00:00 CEST | Press release
Premier global event to highlight how organizations are bringing data to life to power everything from AI to BI Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world.
Axinn Appoints Rachael Philbin as Chief Innovation Officer27.4.2026 15:00:00 CEST | Press release
Appointment Reflects Firm's Vision for the Future of Legal Practice Axinn, Veltrop & Harkrider LLP today announced the appointment of Rachael Philbin as Chief Innovation Officer, reinforcing the firm’s continued investment in advanced solutions and technology for legal services delivery. Philbin joins from Proskauer Rose LLP, where she served as Innovation & Transformation Officer. Based in Axinn's New York office, she will lead the firm’s AI and legal technology initiatives as well as knowledge management efforts, accelerating adoption and integration across its antitrust, intellectual property, and litigation practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427277725/en/ Rachael Philbin joins Axinn, Veltrop & Harkrider LLP as Chief Innovation Officer. “As Axinn continues to grow, we are making deliberate investments in the capabilities that enable our lawyers to deliver service and results at the highest level
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
